Logo

Roche and Structural Genomix Pen Drug Development Deal

Sep 09, 2004

NEW YORK, Sept. 9 (GenomeWeb News) - Roche and Structural Genomix today said they would collaborate on a project to discover new anti-viral therapeutics. SGX will discover small molecule inhibitors that Roche will develop and commercialize worldwide.

 

Under the terms of the agreement, SGX will receive from Roche an upfront payment, research funding, and milestone payments during product development, as well as royalties from product sales.

 

Stephen Burley, chief scientific officer of SGX, said in a statement that the move was consistent with the company's strategy to use its FAST technology to discover drug candidates for its partners, as well as oncology candidates for SGX to develop.

 

SGX's FAST technology identifies drug candidates with a fragment-based approach using high-throughput protein crystallography, computational chemistry and parallel synthesis.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.